As Genome-Editing Evolves, So Do The Investment Opportunities | Page 2 of 2 | ETF Trends

Top holdings include Intellia Therapeutics 10.5%, Illumina 7.8%, Editas Medicine 6.9%, Invitae Corp 6.6%, Celegene 3.8% and Bluebird Bio 3.6%.

The fund tries to help investors take on a thematic multi-capitalization exposure to innovative elements that cover advancements in gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations. These advancements can also translate over to growth potential, potentially providing investors with long-term alpha with low correlation relative to traditional growth strategies.

Furthermore, the active management team behind the ARKG strategy combines a top-down and bottom-up research methodology to identify innovative companies and convergence across markets.

Financial advisors who are interested in learning more about the investment opportunities in genomic sequencing can register for the Tuesday, May 15 webcast here.